▶ GHRP-2 · SUBTOPIC · SAFETY PROFILE
GHRP-2 Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of GHRP-2.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of GHRP-2. Severity, frequency, and attribution depend on the source publication.
- Transient hunger (mild)
- Mild cortisol elevation
- Mild prolactin elevation
- Flushing
- Injection-site reactions
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for GHRP-2.
- Concurrent rhGH not recommended
- Glucocorticoids may blunt response
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for GHRP-2 in the published record:
- Active malignancy
- Pituitary tumor
- Pregnancy/lactation
FDA REGULATORY STATUS
Not FDA-approved. Research-use only in the United States.
WADA REGULATORY STATUS
Prohibited at all times under WADA Section S2 (growth-hormone-secretagogue sub-category).
SAFETY Q+A FROM LITERATURE
▶ Is GHRP-2 FDA-approved?
Not in the United States. Pralmorelin (the diagnostic formulation) is approved in Japan for GH-deficiency testing.
▶ Is GHRP-2 WADA-prohibited?
Yes. GHRP-2 is prohibited at all times under WADA Section S2 in the growth-hormone-secretagogue sub-category.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Bowers CY, Reynolds GA, Durham D, et al.. Growth hormone-releasing peptide-2: A diagnostic agent for pediatric GH deficiency. Endocrine 2001. link
- Smith RG, Van der Ploeg LH, Howard AD, et al.. Pharmacology and effects of growth hormone-releasing peptides. Endocr Rev 1997. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25